Needham & Company downgraded ResMed (NYSE: RMD) from Hold to Underperform on increasing reimbursement and competitive pressures.Analyst Mike Matson commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE